<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430651</url>
  </required_header>
  <id_info>
    <org_study_id>CT/04.14</org_study_id>
    <nct_id>NCT00430651</nct_id>
  </id_info>
  <brief_title>Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)</brief_title>
  <official_title>Multicenter Randomized Phase III Study Comparing Docetaxel With Carboplatin Versus Docetaxel Single Agent as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (NSCLC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <brief_summary>
    <textblock>
      This trial will compare the effectiveness of Docetaxel with or without Carboplatin as second
      line chemotherapy in patients with Non-Small Cell Lung Cancer, who have not been treated
      previously with Docetaxel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the overall survival between the two treatment groups</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the objective response rates between the two treatment groups</measure>
    <time_frame>Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation and comparison of the toxicity between the two treatment groups</measure>
    <time_frame>Toxicity assessment on each chemotherapy cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement and comparison of the health-related quality of life of patients on both treatment groups</measure>
    <time_frame>Assessment every two cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel + Carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed NSCLC.

          -  ECOG Performance Status 0-2.

          -  No previous treatment with Docetaxel.

          -  Measurable Disease.

          -  Brain metastases that have been treated with radiotherapy should be stable and
             asymptomatic.

          -  Adequate liver kidney and bone marrow function.

          -  Patients must be able to understand the nature of this study and give written informed
             consent.

        Exclusion Criteria:

          -  Active cardiac disease: unstable angina or onset of angina within last 3 months,
             myocardial infarction within 6 months, congestive heart failure &gt; class II, cardiac
             ventricular arrhythmias requiring anti-arrhythmic therapy.

          -  Women who are pregnant or lactating.

          -  Unknown HIV, chronic hepatitis B or chronic hepatitis C infections.

          -  Serious neurologic or psychiatric disease.

          -  Second primary malignancy within the past 5 years, except nonmelanomas skin cancer or
             in situ carcinoma of the cervix.

          -  Active uncontrolled infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassilis Georgoulias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete, Dep of Medical Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Crete</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupolis, Dep of Medical Oncology</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;IASO&quot; General Hospital of Athnes, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Laikon&quot; General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Sotiria&quot; General Hospital, 1st, 3rd, 6th, 7th, 8th Dep of Pulmonary Diseases</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401 Military Hospital, Medical Oncology Unit</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Air Forces Military Hospital, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Metaxa's&quot; Anticancer Hospital of Pireaus</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Theagenion&quot; Anticancer Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <last_update_submitted>January 27, 2009</last_update_submitted>
  <last_update_submitted_qc>January 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>V.Georgoulias</name_title>
    <organization>Hellenic Oncology Research Group</organization>
  </responsible_party>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>2nd line chemotherapy</keyword>
  <keyword>Docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

